LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor

BACKGROUND: ACX-362E, a novel DNA polIIIC inhibitor, is a narrow-spectrum antibacterial selectively active against certain Gram-positive bacteria, including Clostridioides difficile (MIC(90) = 4 µg/mL). The objectives of this phase I study was to assess the safety, pharmacokinetics, and fecal microb...

Descripción completa

Detalles Bibliográficos
Autores principales: Garey, Kevin W, Kankam, Martin, Mercier, Julie, Seng Yue, Corinne, Ducharme, Murray, Gonzales-Luna, Anne J, Jahangir Alam, M, Begum, Khurshida, Silverman, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810073/
http://dx.doi.org/10.1093/ofid/ofz415.2490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810073/
http://dx.doi.org/10.1093/ofid/ofz415.2490

Ejemplares similares